PRAX - Praxis Precision Medicines

-

$undefined

N/A

(N/A)

Praxis Precision Medicines NASDAQ:PRAX Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.

Location: | Website: praxismedicines.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.033B

Cash

357M

Avg Qtr Burn

-24.87M

Short % of Float

17.83%

Insider Ownership

0.50%

Institutional Own.

-

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details
Essential tremor

Big Mover™

Susp. Mover™

Phase 3

Data readout

PRAX-628 Details
Epilepsy, Focal Onset Seizures

Phase 2/3

Data readout

PRAX-628 Details
Epilepsy, Focal Onset Seizures

Phase 2b

Data readout

PRAX-628 Details
Epilepsy, Focal Onset Seizures

Phase 2b

Update

Phase 2

Data readout

PRAX-562 Details
Developmental and Epileptic Encephalopathy

Phase 2

Data readout

PRAX-222 Details
Developmental and Epileptic Encephalopathy

Phase 1/2

Data readout

Failed

Discontinued

Failed

Discontinued